Abstract Small interfering RNAs (siRNAs) have
been proven as promising therapeutics for treating brain diseases owing
to their high specificity for pathogenic targets, their relatively low
dose requirement for therapeutic effect, and the simplicity of the drug
development process. Nanotechnology can enable siRNA to
overcome issues relating to during circulation, brain entry, and
diseased tissue/cell targeting by engineering siRNA and related delivery
carriers into nanoparticles, together with chemical and biological
modifications. A biomimetic camouflage strategy,
glycemia-controlled GLUT1 receptor-mediated transport, and tight
junction opening agents can be potentially employed to help siRNA
nanomedicine pass the BBB for more effective brain disease therapy. Nanotechnology-Based.pdf
|